Comparative Pharmacology
Head-to-head clinical analysis: HISTAFED versus PERIACTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HISTAFED versus PERIACTIN.
HISTAFED vs PERIACTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
Cyproheptadine is a first-generation antihistamine with anticholinergic and antiserotonergic properties. It acts as a competitive antagonist at histamine H1 receptors and serotonin 5-HT2 receptors, thereby inhibiting histamine-mediated allergic symptoms and serotonin-mediated effects such as increased gastrointestinal motility and vascular permeability.
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
4 mg orally three times daily; adjust as needed. Maximum: 32 mg/day.
None Documented
None Documented
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
10-12 hours terminal elimination half-life; steady-state reached in 2-3 days
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Renal (40-50% as metabolites, <5% unchanged); biliary/fecal (minor, ~10-20%)
Category C
Category C
Antihistamine/Decongestant Combination
Antihistamine